


in which

R represents hydrogen or acetyl,

R₁ represents benzoyl or R₂-O-CO- in which R₂ represents t-butyl, and

Ar represents phenyl or α - or β -naphthyl, said phenyl or naphthyl being unsubstituted or substituted by C₁₋₄ alkyl, C₁₋₄ alkoxy, halogen, or CF₃, or Ar represents 2- or 3-thienyl or 2- or 3-furyl, said thienyl or furyl being unsubstituted or substituted by halogen.

141. A taxoid of the formula:



in which G₁ represents hydrogen or acetyl.

142. 4 α -10 β -diacetoxy-2 α -benzoyloxy-5 β ,20-epoxy-1 β -hydroxy-7 β ,8 β -methylene-9-oxo-19-nor-11-taxen-13 α -yl (2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate.--

REMARKS

Consideration of this application, as amended, is respectfully requested. Applicants have cancelled claims 1-4, 30-53, and 79-102 without prejudice, leaving claims 5, 13, 24, 54, 62, 73, and 103-139 pending and adding new claims 140-142.

As applicants will demonstrate, these new claims define clearly allowable subject matter that unquestionably interferes with the claims of U.S. Patent No. 5,254,580 to Chen et al., assigned to Bristol-Myers Squibb Company (BMS).¹ Before discussing the interference issues, however, applicants will first address several preliminary matters.

¹ Throughout the rest of this paper, applicants will refer to this patent as the "BMS patent".